Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Regorafenib and Nivolumab Plus Chemotherapy in Patients With Unresectable Advanced/Recurrent Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma

NCT05394740 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT05394740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05394740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Regorafenib and Nivolumab Plus Chemotherapy in Patients With Unresectable Advanced/Recurrent Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 1/2
Overall status
Completed
Start date
June 6, 2022
Completion date
August 25, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma